logo.jpg
Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
April 08, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, April 8, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
March 11, 2021 01:00 ET | Addex Therapeutics
Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) Balance sheet further strengthened by $11.5M fundraising on January 11, 2021Three clinical studies in neurology programs...
logo.jpg
Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021
March 09, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that...
logo.jpg
Addex to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, March 4, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
February 17, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder
February 16, 2021 01:00 ET | Addex Therapeutics
Review from Linköping University Published in Alcohol and Alcoholism Journal Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical...
logo.jpg
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
January 21, 2021 01:00 ET | Addex Therapeutics
      First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Geneva, Switzerland, January 21, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical...
logo.jpg
Addex to Present at the Baader Helvea Swiss Equities Conference
January 12, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, January 12, 2021 -  Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities
January 11, 2021 16:00 ET | Addex Therapeutics
Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex Announces Pricing of $10.0 Million Global Offering
January 06, 2021 21:00 ET | Addex Therapeutics
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...